Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Herceptin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

Mylan gets first biosimilar Herceptin OK from FDA

Mylan gets first biosimilar Herceptin OK from FDA Mylan has become the first pharma company to win US approval for a biosimilar of Roche’s big-selling cancer antibody Herceptin. ... have suggested it will start making revenues from the drug in 2019 – the year in which Roche’s US patent on

First Herceptin biosimilar cleared in Europe

First Herceptin biosimilar cleared in Europe means it can now threaten the CHF 2.1bn in European sales achieved by Herceptin last year. ... Roche is claiming patent protection for Herceptin in the US out to 2019, but its EU patents expired in 2014.

Building a bright future

Building a bright future Herceptin while taking a buffeting over trading in the US, despite European growth contributing strongly to $2.96bn second quarter revenues. ... mission.”. It has manoeuvered into pole position to grab a significant slice of Roche’s $2bn-a-year

CHMP backs maintenance therapy for Tesaro's Zejula

CHMP backs maintenance therapy for Tesaro's Zejula The CHMP recommended approval of two biosimilars, namely Samsung Bioepis' Ontruzant (trastuzumab) - the first biosimilar of Roche's breast cancer therapy Herceptin to get a positive opinion in the EU - and

Amgen's Mvasi is first FDA-approved cancer biosimilar

Amgen's Mvasi is first FDA-approved cancer biosimilar At the ODAC meeting, the panel also backed approval of Mylan's biosimilar of Roche's breast cancer therapy Herceptin (trastuzumab) that, like Avastin, loses US patent protection in 2019.

[ Previous 5 results ] 8 9 10 11 12 13 14 15 16 17 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics